Table 1. ZNF545 methylation and clinicopathologic features of breast tumors.
| Clinicopathological features | Number (n = 128) | ZNF545 promoter methylated status | P value | |
| methylated | unmethylated | |||
| Age | 0.232 | |||
| ≤40 | 14 | 2 (14%) | 12 (86%) | |
| >40 | 102 | 33 (32%) | 69 (68%) | |
| unknown | 12 | 2 (17%) | 10 (83%) | |
| grade | 0.658 | |||
| I | 7 | 2 (29%) | 5 (71%) | |
| II | 81 | 26 (32%) | 55 (68%) | |
| III | 6 | 2 (33%) | 4 (67%) | |
| unknown | 34 | 7 (21%) | 27 (79%) | |
| Tumour size | 0.302 | |||
| <2.0 cm | 42 | 10 (24%) | 32 (76%) | |
| ≥2.0 cm≤5.0 cm | 63 | 21 (33%) | 42 (67%) | |
| >5.0 cm | 9 | 4 (44%) | 5 (56%) | |
| unknown | 14 | 2 (14%) | 12 (86%) | |
| Lymph node metastasis | 0.371 | |||
| Positive | 54 | 18 (33%) | 36 (67%) | |
| Negative | 60 | 17 (28%) | 43 (72%) | |
| unknown | 14 | 2 (14%) | 12 (86%) | |
| ER status | 0.501 | |||
| Positive | 54 | 19 (35%) | 35 (65%) | |
| Negative | 43 | 12 (28%) | 31 (72%) | |
| unknown | 31 | 5 (16%) | 6 (84%) | |
| PR status | 0.403 | |||
| Positive | 44 | 14 (32%) | 30 (68%) | |
| Negative | 53 | 17 (32%) | 36 (68%) | |
| unknown | 31 | 6 (19%) | 25 (81%) | |
| HER2 status | 0.068 | |||
| >+++ | 6 | 2 (33%) | 4 (67%) | |
| ++ | 50 | 21 (42%) | 29 (58%) | |
| <+ | 39 | 8 (21%) | 31 (79%) | |
| unknown | 32 | 6 (19%) | 26 (81%) | |
| p53 expression | 0.540 | |||
| Positive | 37 | 13 (35%) | 24 (65%) | |
| Negative | 49 | 14 (29%) | 35 (71%) | |
| unknown | 42 | 10 (24%) | 32 (76%) | |
| phase | 0.762 | |||
| 1 | 35 | 10 (29%) | 25 (71%) | |
| 2 | 54 | 17 (31%) | 37 (69%) | |
| 3 | 25 | 8 (32%) | 17 (68%) | |
| 4 | 1 | 0 (0%) | 1 (100%) | |
| unknown | 13 | 2 (15%) | 11 (85%) | |